Edition:
United States

Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

64.78USD
4:03pm EDT
Change (% chg)

$-0.42 (-0.64%)
Prev Close
$65.20
Open
$65.38
Day's High
$65.41
Day's Low
$64.54
Volume
660,756
Avg. Vol
659,036
52-wk High
$65.82
52-wk Low
$46.86

Chart for

About

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock)... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $31,890.08
Shares Outstanding(Mil.): 489.11
Dividend: 0.10
Yield (%): 0.64

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.18
EPS (TTM): -- -- --
ROI: -- 15.15 14.60
ROE: -- 16.38 13.87

BRIEF-Zoetis announces pricing of $1.25 bln of senior notes

* Zoetis Inc - ‍agreed to sell $1.25 billion of senior notes, consisting of $750 million aggregate principal amount of 3.000% senior notes due 2027​

Sep 05 2017

BRIEF-Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines

* Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines Source text for Eikon: Further company coverage:

Aug 31 2017

BRIEF-Anatara and Zoetis to negotiate terms of an international Detach commercial agreement

* Anatara and Zoetis to negotiate terms of an international Detach® commercial agreement Source text for Eikon: Further company coverage:

Aug 21 2017

BRIEF-Zoetis reports Q2 earnings per share $0.50

* Q2 earnings per share view $0.53 -- Thomson Reuters I/B/E/S

Aug 08 2017

BRIEF-High Court of Ireland approves acquisition of Nexvet by Zoetis Inc's unit

* High Court of Ireland has approved acquisition of Nexvet by Zoetis Inc through its unit Source text for Eikon: Further company coverage:

Jul 28 2017

BRIEF-Zoetis gets grant from Bill & Melinda Gates foundation to develop sustainable livestock production in sub-Saharan Africa

* Will receive $14.4 million grant from Bill & Melinda Gates foundation over next 3 years

May 08 2017

BRIEF-Zoetis Q1 adjusted earnings per share $0.53

* Q1 earnings per share view $0.48 -- Thomson Reuters I/B/E/S

May 04 2017

BRIEF-Zoetis gets European Commission marketing authorization for Cytopoint

* Zoetis receives european commission marketing authorization for Cytopoint® (lokivetmab) Source text for Eikon: Further company coverage:

Apr 26 2017

BRIEF-Zoetis to acquire Nexvet for US$6.72 in Cash Per Share

* Zoetis to acquire Nexvet Biopharma, an innovator in monoclonal antibody therapies for companion animals

Apr 13 2017

BRIEF-Zoetis CEO's 2016 total compensation was $9.5 million

* CEO Juan Ramón Alaix's 2016 total compensation was $9.5 million versus $8.7 million in 2015 Source text:(http://bit.ly/2nRVXcH) Further company coverage:

Mar 31 2017

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $65.95 -0.04
Bayer AG (BAYGn.DE) €109.90 -0.60
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.25 +0.73
Eli Lilly and Co (LLY.N) $81.73 -0.79

Earnings vs. Estimates